David Nierengarten Analyst PerformanceManaging Director, Equity Research at WedbushDavid Nierengarten is a stock analyst at Wedbush focused in the medical sector, covering 42 publicly traded companies. Over the past year, David Nierengarten has issued 76 stock ratings, including buy and hold recommendations. While full access to David Nierengarten's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Nierengarten's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings123 Last 11 YearsBuy Recommendations78.51% 95 Buy RatingsCompanies Covered42 Unique Companies Ratings Distribution121RatingsDistribution of strong buy, buy, hold, and sell ratings by David Nierengarten.RatingPercentageCount Strong Buy0.0%0 ratings Buy78.5%95 ratings Hold21.5%26 ratings Sell0.0%0 ratingsOut of 121 total stock ratings issued by David Nierengarten at Wedbush, the majority (78.5%) have been Buy recommendations, followed by 21.5% Hold.Best & Worst CallsBest Call0000.0%BEAMMay 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%DAREApr 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ95.2% of companies on NASDAQ40 companiesNYSE2.4% of companies on NYSE1 companyNYSEAMERICAN2.4% of companies on NYSEAMERICAN1 companyDavid Nierengarten, an analyst at Wedbush, currently covers 42 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical40 companies95.2%Miscellaneous1 company2.4%Manufacturing1 company2.4%David Nierengarten of Wedbush specializes in stock coverage within the Medical sector, with additional focus on and Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE34 companies81.0%MED - DRUGS5 companies11.9%Miscellaneous1 company2.4%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company2.4%SURGICAL & MEDICAL INSTRUMENTS1 company2.4% About David NierengartenDavid Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models. In addition, David has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor. David received his B.S. in Biochemistry from the University of Wisconsin-Madison, and Ph.D. in Molecular and Cell Biology from the University of California at Berkeley. David Nierengarten's Ratings History at Wedbush Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsABVXAbivax6/2/2026Upgrade$129.69$90.00Neutral$0.0000.00% ROIODTXOdyssey Therapeutics6/2/2026Initiated Coverage$16.96$30.00Outperform$0.0000.00% ROICOGTCogent Biosciences5/29/2026Reiterated Rating$35.21$55.00Outperform$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock5/28/2026Initiated Coverage$25.21$35.00Outperform$0.0000.00% ROINUVLNuvalent5/28/2026Reiterated Rating$107.38$125.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics5/27/2026Boost Price Target$84.60$135.00Outperform$0.0000.00% ROICOAGHemab Therapeutics5/26/2026Initiated Coverage$25.89$42.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics5/12/2026Reiterated Rating$14.42$12.00Neutral$0.0000.00% ROISTTKShattuck Labs5/8/2026Boost Price Target$6.48$11.00Outperform$0.0000.00% ROINUVBNuvation Bio5/5/2026Reiterated Rating$4.66$11.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CATXPerspective Therapeutics5/5/2026Reiterated Rating$3.78$11.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/29/2026Boost Price Target$54.04$59.00Outperform$0.0000.00% ROICATXPerspective Therapeutics4/20/2026Reiterated Rating$4.20$11.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/16/2026Boost Price Target$46.31$58.00Outperform$0.0000.00% ROINVCRNovoCure4/16/2026Reiterated Rating$12.24$18.00Neutral$0.0000.00% ROINUVBNuvation Bio4/16/2026Reiterated Rating$4.83$11.00Outperform$0.0000.00% ROIFENCAdherex Technologies4/16/2026Reiterated Rating$6.50$13.00Outperform$0.0000.00% ROISYRESpyre Therapeutics4/13/2026Boost Price Target$64.47$80.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals4/13/2026Reiterated Rating$10.54$22.00Outperform$0.0000.00% ROINUVLNuvalent4/8/2026Reiterated Rating$102.25$125.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals4/7/2026Reiterated Rating$9.09$22.00Outperform$0.0000.00% ROINUVBNuvation Bio4/2/2026Reiterated Rating$4.50$11.00Outperform$0.0000.00% ROISRRKScholar Rock4/1/2026Boost Price Target$49.16$58.00Outperform$0.0000.00% ROIORICOric Pharmaceuticals4/1/2026Lower Price Target$12.67$17.00Outperform$0.0000.00% ROIBCAXBicara Therapeutics3/31/2026Reiterated Rating$19.52$30.00Outperform$0.0000.00% ROINUVBNuvation Bio3/27/2026Reiterated Rating$4.41$11.00Outperform$0.0000.00% ROICATXPerspective Therapeutics3/18/2026Reiterated Rating$4.95$11.00Outperform$0.0000.00% ROICOGTCogent Biosciences3/17/2026Reiterated Rating$35.68$55.00Outperform$0.0000.00% ROIARGXargenex3/9/2026Reiterated Rating$717.80$1,000.00Outperform$0.0000.00% ROISTTKShattuck Labs3/6/2026Boost Price Target$5.10$8.00Outperform$0.0000.00% ROITCRXTScan Therapeutics3/5/2026Boost Price Target$1.08$5.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics3/3/2026Boost Price Target$67.77$95.00Outperform$0.0000.00% ROIBEAMBeam Therapeutics2/25/2026Boost Price Target$32.29$65.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International2/25/2026Boost Price Target$43.50$53.00Outperform$0.0000.00% ROIABVXAbivax2/24/2026Initiated Coverage$132.91$110.00Outperform$0.0000.00% ROIORICOric Pharmaceuticals2/24/2026Reiterated Rating$11.71$20.00Outperform$0.0000.00% ROIIRONDisc Medicine2/17/2026Lower Price Target$55.99$88.00Outperform$0.0000.00% ROINUVBNuvation Bio2/10/2026Reiterated Rating$5.69$11.00Outperform$0.0000.00% ROICATXPerspective Therapeutics1/30/2026Reiterated Rating$4.01$11.00Outperform$0.0000.00% ROICOGTCogent Biosciences1/21/2026Reiterated Rating$39.90$55.00Outperform$0.0000.00% ROIGoldman Sachs just told you what to buy (most people missed it) (Ad)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.See the stock positioned to solve AI's biggest power crisisIRONDisc Medicine1/15/2026Reiterated Rating$72.74Outperform$0.0000.00% ROIIMNMImmunome1/15/2026Reiterated Rating$20.76$31.00Outperform$0.0000.00% ROINVCRNovoCure1/15/2026Reiterated Rating$13.77$18.00Neutral$0.0000.00% ROIARGXargenex1/14/2026Reiterated Rating$810.51$1,000.00Outperform$0.0000.00% ROIBCAXBicara Therapeutics1/13/2026Reiterated Rating$17.43$30.00Outperform$0.0000.00% ROIORICOric Pharmaceuticals1/13/2026Reiterated Rating$9.15$20.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International1/13/2026Boost Price Target$41.12$50.00Outperform$0.0000.00% ROIGBIOGeneration Bio12/16/2025Set Price Target$5.39$5.50Outperform$0.0000.00% ROIORICOric Pharmaceuticals12/8/2025Reiterated Rating$11.00$20.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International12/2/2025Reiterated Rating$40.07$48.00Outperform$0.0000.00% ROINUVLNuvalent11/17/2025Reiterated Rating$108.00$125.00Outperform$0.0000.00% ROIARGXargenex11/14/2025Boost Price Target$894.31$1,000.00Outperform$0.0000.00% ROIANABAnaptysBio11/10/2025Reiterated Rating$33.21$50.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics11/7/2025Lower Price Target$9.84$7.00Neutral$0.0000.00% ROIXNCRXencor11/6/2025Reiterated Rating$14.24$26.00Outperform$0.0000.00% ROINTLAIntellia Therapeutics10/30/2025Set Price Target$12.37$9.00$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International10/28/2025Reiterated Rating$40.45$48.00Outperform$0.0000.00% ROIFATEFate Therapeutics10/27/2025Upgrade$1.65$7.00Outperform$0.0000.00% ROIIRONDisc Medicine10/17/2025Boost Price Target$74.36$110.00Outperform$0.0000.00% ROIANABAnaptysBio10/15/2025Boost Price Target$31.85$70.00Outperform$0.0000.00% ROIARGXargenex10/13/2025Boost Price Target$796.92$880.00Outperform$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International10/13/2025Boost Price Target$37.89$44.00Outperform$0.0000.00% ROINUVBNuvation Bio10/13/2025Reiterated Rating$3.73$6.00Outperform$0.0000.00% ROISTTKShattuck Labs9/8/2025Initiated Coverage$1.55$4.00Outperform$0.0000.00% ROINUVBNuvation Bio9/8/2025Reiterated Rating$3.88$6.00Outperform$0.0000.00% ROINUVLNuvalent9/8/2025Reiterated Rating$80.89$115.00Outperform$0.0000.00% ROIXNCRXencor9/2/2025Reiterated Rating$8.55$26.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals8/28/2025Reiterated Rating$12.10$22.00Outperform$0.0000.00% ROIGBIOGeneration Bio8/13/2025Downgrade$4.05$7.00Neutral$0.0000.00% ROIXNCRXencor8/7/2025Lower Price Target$7.49$26.00Outperform$0.0000.00% ROIIMAImageneBio7/25/2025Lower Price Target$16.32$23.00Neutral$0.0000.00% ROIARGXargenex6/24/2025Reiterated Rating$550.14$715.00Outperform$0.0000.00% ROICATXPerspective Therapeutics6/23/2025Reiterated Rating$3.53$11.00Outperform$0.0000.00% ROIARGXargenex6/11/2025Reiterated Rating$575.46$715.00Outperform$0.0000.00% ROINUVBNuvation Bio6/11/2025Reiterated Rating$2.14$5.00Outperform$0.0000.00% ROITLXTelix Pharmaceuticals6/5/2025Initiated Coverage$17.48$22.00Outperform$0.0000.00% ROIBPMCBlueprint Medicines6/2/2025Downgrade$101.15$129.00Neutral$0.0000.00% ROIITOSiTeos Therapeutics5/28/2025Downgrade$10.43$12.00Neutral$0.0000.00% ROINTLAIntellia Therapeutics5/19/2025Reiterated Rating$9.09$10.00Neutral$00.0000.00% ROINUVBNuvation Bio5/15/2025Reiterated Rating$2.24$5.00Outperform$0.0000.00% ROIBPMCBlueprint Medicines4/16/2025Reiterated Rating$79.46$128.00Outperform$0.0000.00% ROINVCRNovoCure4/16/2025Lower Price Target$15.66$27.00Neutral$00.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/16/2025Reiterated Rating$20.59$34.00Outperform$00.0000.00% ROIARGXargenex4/11/2025Reiterated Rating$577.38$715.00Outperform$000.0000.00% ROIIMNMImmunome3/20/2025Reiterated Rating$8.64$33.00Outperform$00.0000.00% ROISTROSutro Biopharma3/14/2025Downgrade$12.50$20.00Neutral$00.0000.00% ROIFATEFate Therapeutics3/6/2025Reiterated Rating$0.91$5.00Neutral$0.0000.00% ROISWTXSpringWorks Therapeutics2/10/2025Reiterated Rating$54.00$77.00Outperform$0.0000.00% ROIBCAXBicara Therapeutics2/6/2025Initiated Coverage$12.72$31.00Outperform$00.0000.00% ROIANABAnaptysBio2/3/2025Reiterated Rating$17.27$40.00Outperform$00.0000.00% ROIYour $29.97 book is free today (Ad)Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.Normally $29.97. Today it's free. Grab your copy now.BPMCBlueprint Medicines1/13/2025Reiterated Rating$93.42$124.00Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
